Not sure I see the potential benefit in "pooling" the data into a single calculation for the reasons Bear & Iconoclast state ... however, it is still all amalgamated study data, that look at several different angles ... and can be alagmated into a "case" for moving forward should results and safety align toward patient and payor benefits in a positive way, potentially, and hopefully?

Trying to follow this Biogen story, and recent FDA approval pressure & initiatives ... just hoping for the best and most compelling data possible to differentiate sub-study & secondary data, marginalize and overcome the "overall" TLD shortcoming, and build a cogent case with whatever we have to fight with ... hopefully there is enough good data relative to patient benefit and market need to set the academic/scientific/clinical and "PATIENT ADVOCACY" domains on fire with demand. 

data data data? ... okay let's see what ya got?